Quince Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $16.9M
- Price
- $17.25
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.37%
- Volume
- 10.1K
Quote data as of 7:03 AM ET
About
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.
Quick stats
Shares outstanding978.0K
Computed float763.7K
Float sourceUnknown
Cash runway (months)Unknown
Dilution risk—
Has warrants—
Has convertibles—
Active shelf (Shelf registration (e.g. Form S-3) currently in effect — the company is pre-cleared to issue and sell new shares quickly. A standing dilution risk.)—
Active ATM (At-the-market offering — a program to sell newly issued shares directly into the open market at prevailing prices, diluting existing holders over time.)—
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001662774
Websitehttps://www.quincetx.com
AI Summary
AI-generated2mo agocriticalmixedm and aQuince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary Pipeline
Quince Therapeutics has acquired clinical-stage biotech Orphai Therapeutics to secure its lead asset LAM-001, an inhaled rapamycin formulation for pulmonary diseases.
To fund the acquisition and extend its cash runway to the end of 2028, Quince executed a private placement raising up to $187 million, including $115 million in upfront proceeds.
The transaction is highly dilutive: existing Quince shareholders will own approximately 6.9% of the fully-diluted company, while PIPE investors will hold 61.2% and former Orphai shareholders 31.9%.
Red flags
- Extreme dilution: existing shareholders retain only ~6.9% of fully-diluted equity
- PIPE investors acquire majority control (~61.2%) of the company
- Offering priced at $0.7975 per share on an as-converted basis; verify discount to market price